- Home
- LGO vs PLRX Comparison
LGO vs PLRX Comparison
Compare LGO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGO | PLRX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 93.3M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LGO | PLRX |
|---|---|---|
| Price | $1.23 | $1.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 11 |
| Target Price | $3.30 | ★ $3.79 |
| AVG Volume (30 Days) | 561.5K | ★ 933.0K |
| Earning Date | 11-12-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $111,884,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $53.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $1.10 |
| 52 Week High | $2.70 | $12.88 |
Technical Indicators
Market Signals| Indicator | LGO | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 47.62 |
| Support Level | $1.05 | $1.28 |
| Resistance Level | $1.24 | $1.38 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 90.81 | 55.26 |
Price Performance
Historical ComparisonAbout LGO Largo Inc.
Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.